The Feinstein Institutes for Medical Research

The Picower Institute for Medical Research

Cytokine Pharmasciences, Inc.

Onconox Aps

Other

Cpsi Stockholder Trust

The Picower Institute of Medical Research

Ganial Immunotherapeutics, Inc.

Yousef Al-Abed

Richard J Bucala

Kevin J Tracey

Kai Fan Cheng

Huan Yang

Betty A Diamond

Ferdinando Nicoletti

Gianni Garotta

Edmund Miller

Yinzhong Zhang

Marc Symons

Anthony Cerami

Peter C Ulrich

Peter Senter

Robert A Mitchell

Svetlana Ivanova

Mohindra Seepersaud

Rosamaria Ruggieri

Ahmad Altiti

Ferninando Nicoletti

Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.

Compounds for use in synthesis of peptidomimetics

The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.

HMGB1 antagonist treatment of severe sepsis

The present invention is related to the use of HMGB1 antagonists in the treatment and/or prevention and/or inhibition of acute lung injury in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists, in particular K883, in an effective amount to treat and/or prevent and/or inhibit this condition.

HMGB1 antagonist treatment of acute lung injury

Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Treatment of HMGB1-mediated inflammation

The present invention is related to HMGB1 antagonists and, in particular, HMGB1 tetramer peptidomimetics which have been stabilized with at least one azatide linkage, such as K883. The present invention is also related to pharmaceutical compositions comprising HMGB1 antagonists such as K883.

HMGB1 antagonist

The present invention is related to the use of HMGB1 antagonists, specifically derivatives of K883 in the treatment and/or prevention and/or inhibition of neuropathy pain, and in particular diabetic neuropathy in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.

HMGB1 antagonist treatment of diabetic peripheral neuropathy

Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics. Methods for preparing and using ureases, carbazides, semicarbazides, beta-peptides, azapeptides, and other peptidomimetics and azapeptide conjugates, and uses of ureases, carbazides, semicarbazides, beta-peptides, azapeptides in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are also described.

Thiosemicarbazates and uses thereof

Methods and compounds are described for treating solid tumors, and in particular, malignant, neoplastic solid tumors such as glioblastoma and medulloblastoma, by inhibiting protein kinase MRK/ZAK activity. Also provided are pharmaceutical composition containing a MRK/ZAK inhibitor compound and a pharmaceutically acceptable carrier and a method of sensitizing tumor cells to radiation therapy comprising administering an effective amount of the MRK/ZAK inhibitor compound.

Treatment of solid tumors by inhibiting MRK/ZAK

Compounds and compositions are provided which inhibit MIF. Methods of treatment of melanoma and colon cancers are also provided.

Inhibition of macrophage migration inhibitory factor in melanoma and colon cancer

Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for reating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.

Method for treating a neurological disorder associated with hypoxia using a small moleucule MIF inhibitor

Methods of treating an astrocytoma with agents effective to inhibit microglia function are provided, as well as methods of enhancing the efficacy of brain tumor radiation therapy on an astrocytoma in a subject. Also provided are methods of treating other solid tumor types, and tumor cell invasion, with guanylhydrazone compounds.

Growing community of inventors

Locust Valley, NY, United States of America

Yousef Al-Abed